Article Versions Notes

Prezioso C, Grimaldi A, Landi D, Nicoletti CG, Brazzini G, Piacentini F, Passerini S, Limongi D, Ciotti M, Palamara AT, et al. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment. Viruses. 2021; 13(9):1684. https://doi.org/10.3390/v13091684

Prezioso, Carla, Alfonso Grimaldi, Doriana Landi, Carolina Gabri Nicoletti, Gabriele Brazzini, Francesca Piacentini, Sara Passerini, Dolores Limongi, Marco Ciotti, Anna Teresa Palamara, and et al. 2021. "Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment" Viruses 13, no. 9: 1684. https://doi.org/10.3390/v13091684

Prezioso, C., Grimaldi, A., Landi, D., Nicoletti, C. G., Brazzini, G., Piacentini, F., Passerini, S., Limongi, D., Ciotti, M., Palamara, A. T., Marfia, G. A., & Pietropaolo, V. (2021). Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment. Viruses, 13(9), 1684. https://doi.org/10.3390/v13091684